Induction Chemotherapy Followed by Chemo-intensity-modulated Radiotherapy for Locally Advanced Nasopharyngeal Cancer.
Loading...
Embargo End Date
ICR Authors
Authors
Miah, AB
Bhide, SA
Del Rosario, L
Matthews, J
Nicol, R
Tanay, MA
Gupta, S
Zaidi, SH
Newbold, KL
Harrington, KJ
Nutting, CM
Bhide, SA
Del Rosario, L
Matthews, J
Nicol, R
Tanay, MA
Gupta, S
Zaidi, SH
Newbold, KL
Harrington, KJ
Nutting, CM
Document Type
Journal Article
Date
2016-08-01
Date Accepted
2015-12-30
Abstract
AIMS: To determine the toxicity and tumour control rates after chemo-intensity-modulated radiotherapy (chemo-IMRT) for locally advanced nasopharyngeal cancers (LA-NPC). MATERIALS AND METHODS: Patients with LA-NPC were enrolled in a trial to receive induction chemotherapy followed by parotid-sparing chemo-IMRT. The primary site and involved nodal levels received 65 Gy in 30 fractions and at risk nodal levels received 54 Gy in 30 fractions. Incidence of ≥grade 2 subjective xerostomia was the primary end point. Secondary end points included incidences of acute and late toxicities and survival outcomes. RESULTS: Forty-two patients with American Joint Committee on Cancer stages II (12%), III (26%) and IV (62%) (World Health Organization subtype: I [5%]; II [40%]; III [55%]) completed treatment between January 2006 and April 2010 with a median follow-up of 32 months. Incidences of ≥grade 2 acute toxicities were: dysphagia 83%; xerostomia 76%; mucositis 97%; pain 76%; fatigue 99% and ototoxicity 12%. At 12 months, ≥grade 2 subjective xerostomia was observed in 31%, ototoxicitiy in 13% and dysphagia in 4%. Two year locoregional control was 86.2% (95% confidence interval: 70.0-94.0) with 2 year progression-free survival at 78.4% (61.4-88.6) and 2 year overall survival at 85.9% (69.3-93.9). CONCLUSIONS: Chemo-IMRT for LA-NPC is feasible with good survival outcomes. At 1 year, 31% experience ≥grade 2 subjective xerostomia.
Citation
Clinical oncology (Royal College of Radiologists (Great Britain)), 2016, 28 (8), pp. e61 - e67
Source Title
Publisher
ELSEVIER SCIENCE LONDON
ISSN
0936-6555
eISSN
1433-2981
Research Team
Targeted Therapy